The IFCC maintains the JCTLM (Joint Committee for Traceability in Laboratory Medicine) endorsed reference measurement procedure for HbA1c, accepted worldwide as the analytical control for traceability of HbA1c measurement.
To participate in the program manufacturers are required to register and report the results of twenty four samples (two per month) from across the measurement range. The samples are supplied by an IFCC Reference Laboratory.
“The awarding of this certification allows us to report results traceable to the IFCC reference method for quantitative determination of HbA1c,” said Gavin Jones, Diabetes Product Manager EKF Diagnostics. “Together with the existing NGSP certification we achieved from 2012, the IFCC award demonstrates conclusively that Quo-Lab meets all of the demanding standards set by independent certifying bodies.”
Glycated hemoglobin (HbA1c) testing is globally recognized as the gold standard in monitoring of diabetic patients, enabling more complete control of their disease management. The Quo-Lab analyzer offers laboratory accurate results from just 4 µL of blood with a user friendly interface, simplifying the process even further.
Based in Cardiff, United Kingdom, EKF Diagnostics Holdings plc specializes in the development, production and worldwide distribution of point-of-care blood analyzers for use in the detection and management of diabetes, anemia, lactate and kidney related diseases. Its new Molecular division focuses on molecular and companion diagnostics.